Evidence map›Paper›PMID 42137841›Full record

ArticleNarra J2026

Development and diagnostic performance of a novel scoring system for predicting COVID-19 severity in a national referral hospital.

Rikarni Rikarni, Najirman Najirman, Dwi Yulia, Ricvan D Nindrea, Muhammad Ap Yudha, Amalina Amalina

Abstract read
In one paragraph

Article in Narra J, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rikarni RikarniDepartment of Clinical Pathology, Dr. M. Djamil Hospital, Padang, Indonesia.
Najirman NajirmanDepartment of Internal Medicine, Dr. M. Djamil Hospital, Padang, Indonesia.
Dwi YuliaDepartment of Clinical Pathology, Dr. M. Djamil Hospital, Padang, Indonesia.
Ricvan D NindreaDepartment of Education and Research, Dr. M. Djamil Hospital, Padang Indonesia.
Muhammad Ap YudhaDepartment of Internal Medicine, Faculty of Medicine, Universitas Andalas, Padang, Indonesia.
Amalina AmalinaDepartment of Internal Medicine, Faculty of Medicine, Universitas Andalas, Padang, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) shows a wide spectrum of clinical manifestations, ranging from mild illness to severe and critical disease. Early identification of patients at risk of deterioration remains important for timely clinical decision-making. The aim of this study was to develop a novel scoring system for predicting COVID-19 severity in a national referral hospital. This prospective cohort study included patients with confirmed COVID-19 admitted to Dr. M. Djamil Hospital, Padang, Indonesia, from May to December 2021. Demographic, clinical, and laboratory data were collected, and disease severity was classified according to the World Health Organization criteria. Univariate analysis was performed to identify candidate variables, followed by multivariable logistic regression analysis to determine independent predictors of severity. A scoring system was then constructed based on the retained predictors, and its diagnostic performance was evaluated using receiver operating characteristic analysis and the Youden index. Five variables were independently associated with COVID-19 severity: white blood cell count (WBC) ≥ 10,000/mm3, absolute lymphocyte count (ALC) < 1,500/mm3, platelet large cell ratio (PLCR) ≥ 30%, interleukin-6 (IL-6) ≥ 7 pg/mL, and D-dimer ≥500 ng/mL. These variables were incorporated into a scoring system with a maximum total score of 6. Using a cut-off score of 3.5, the model showed a sensitivity of 96.15% and a specificity of 79.03% for differentiating severe from non-severe COVID-19. This study highlights that a novel scoring system based on WBC, ALC, PLCR, IL-6, and D-dimer performed well in predicting COVID-19 severity and may support early risk stratification in hospitalized patients.

Indexed as

COVID-19Severity of Illness IndexAdultAgedFemaleFibrin Fibrinogen Degradation ProductsHumansIndonesiaInterleukin-6Leukocyte CountLymphocyte CountMaleMiddle AgedPredictive Value of TestsProspective StudiesROC CurveFibrin Fibrinogen Degradation Productsfibrin fragment DInterleukin-6COVID-19D-dimernovel scoringpredictionseverity

Identifiers

PMID42137841
PMCPMC13170910

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.